| Name | HUTCHMED (China) Limited |
|---|---|
| Epic | HCM |
| Isin | KYG4672N1198 |
| Index | AIM50 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 278.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £2,422.94 | Debt ratio | n/a |
| Shares in issue | 871.26 | Debt-to-equity ratio | n/a |
| P/E ratio | 29.4 | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 2.76 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | 12 | 52-week high / low | 192.40p / 352.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | HUTCHMED (China) Limited |
|---|---|
| Address | PO Box 309, Ugland House, George Town, Grand Cayman, Cayman Islands, KY1-1104 |
| Telephone | +1 345 949 8066 |
| Website | http://www.hutch-med.com |
| Director | Position |
|---|---|
| Dr Weiguo Su | CEO |
| Mr Dan Eldar | Chairman |
| Ms Ling Yang | Non-Executive Director |
| Dr Renu Bhatia | Non-Executive Director |
| Mr Paul Rutherford Carter | Senior Independent Non-Executive Director |
| Professor Shu Kam Tony | Independent Non-Executive Director |
| Mr Graeme Allan Jack | Independent Non-Executive Director |
| Ms Edith Shih | Non-Executive Director and Company Secretary |
| Mr Johnny Cheng | CFO & Executive Director |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | 48.41 | 73.78 | 76.48 |
| Total non-current assets | 182.93 | 189.56 | 160.59 |
| Inventory / work in progress | 50.26 | 56.69 | 35.76 |
| Trade and other receivables | 160.24 | 152.2 | 164.62 |
| Cash and equivalents | 283.59 | 313.28 | 377.54 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 1279.77 | 1029.44 | 1372.66 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 403.03 | 353.9 | 311.66 |
| Long term liabilities | 133.36 | 38.67 | 21.49 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 536.39 | 392.58 | 333.15 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 743.39 | 636.87 | 1039.51 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 87.13 | 86.48 | 86.45 |
| Minority interests | 12.85 | 26.5 | 52.62 |
| Retained earnings | -870.87 | -971.48 | 5.57 |
| Share premium account | 1522.45 | 1497.27 | 1505.2 |
| Total equity | 743.39 | 636.87 | 1039.51 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 18.38 | -407.69 | -328.32 |
| Pre-tax profit | 58.31 | -410.42 | -215.74 |